XML 64 R52.htm IDEA: XBRL DOCUMENT v3.25.1
Financial Instruments (Details)
€ in Thousands, $ in Thousands, $ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Mar. 31, 2025
CAD ($)
Mar. 31, 2025
EUR (€)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Accounts receivable $ 24,594 $ 55,815    
Canada, Dollars        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Net monetary liabilities 2,358   $ 3,392  
Euro        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Net monetary liabilities $ 4,273     € 3,950
Accounts Receivable | Credit Concentration Risk | GlaxoSmithKline Intellectual Property Development Ltd. (“GSK”):        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Concentration risk, percentage 57.00%      
Accounts Receivable | Credit Concentration Risk | Jazz:        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Concentration risk, percentage   95.00%